CENTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an architic addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 223-16-1760, on the below date:

Data: 117-24, 2005, Name: Holdi A. Dare, Reg. No. 50 775

Signature: Holdi A. Dare, Reg. No. 50 775

BRINKS

Date: <u>June 21, 2006</u> Nan	ne: Heidi A. Dare, Reg. No. 50,775 Signature: TYCOO	C N 1 JOVAC	HOLEL
	N THE UNITED STATES PATENT AND TR	ADEMARK OFFICE	GILSON
In re Appln. of:	Christof Westenfelder		&LIONE
Appln. No.:	10/551,317	Examiner: To Be	Assigned
Filed:	September 29, 2005	Art Unit: To Be A	ssigned
For:	Stem- Cell, Precursor Cell, or Target Cell- Based Treatment of Multiorgan Failure and Renal Dysfunction		
Attorney Docket	t No: 10402-26		
Mail Stop Amendm	ent		

**Commissioner for Patents** P. O. Box 1450 Alexandria VA 22313-1450

**TRANSMITTAL** 

<b>ЛІСХАІ</b>	ilulia, VA 22515-140	<b>70</b>								
Sir:										
Attacl	hed is/are:									
$\boxtimes$	Information Disclos	ure Statei	ment; Form PTO-14	49; copies	S O	f referenc	es A41-A1	00		
$\boxtimes$	Return Receipt Pos	tcard								
Fee c	alculation:									
$\boxtimes$	No additional fee is	required.								
	Small Entity.									
	An extension fee in	an amou	nt of \$ for a _	mon	th	extension	n of time un	der 3	37 C.F.R.	§ 1.136(a).
	A petition or proces	sing fee i	n an amount of \$	under	37	7 C.F.R. §	1.17(	_).		
	An additional filing	ee has b	een calculated as sl	nown belo	w:					
						Sma	II Entity		Not a S	Small Entity
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Add'l Fee	or	Rate	Add'I Fee
Total		Minus				x \$25=	_		x \$50=	
Indep.		Minus				x 100=			x \$200=	
First P	Presentation of Multiple	Dep. Clain	1			+\$180=			+ \$360=	
						Total	\$		Total	\$0
Fee p	payment:									
	A check in the amo	unt of \$	is enclosed.							
	Please charge Dep for this purpose.	osit Acco	unt No. 23-1925 in t	he amoun	t o	f \$	. A copy of	this	Transmit	tal is enclosed
	Payment by credit of	ard in the	e amount of \$	(Form PT	O-	2038 is a	ttached).			
	and any patent ap	plication   ired to e	rized to charge payoprocessing fees und nsure that this par	der 37 CF	R	§ 1.17 a	ssociated v	with	this pape	er (including ar

Respectfully submitted,

une 21, 2006	Heich A. Done
Date	Heidi A. Dare (Reg. No. 50,775)



In re Appln. of: Christof Westenfelder

Appln. No.: 10/551,317

Filed: September 29, 2005

For: Stem- Cell, Precursor Cell, or Target

Cell-Based Treatment of Multiorgan

Failure and Renal Dysfunction

Attorney Docket No: 10402-26

Examiner: To Be Assigned
Art Unit: To Be Assigned

## INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and more particularly in accordance with 37 C.F.R. §1.97(b), Applicant hereby cites the following references:

Patent Number	Date	Applicant
5,197,985	03/1993	Caplan et al.
5,226,914	07/1996	Caplan et al.
5,486,359	01/1996	Caplan et al.
5,591,625	01/1997	Gerson et al.
5,643,736	07/1997	Bruder et al.
5,733,542	03/1998	Haynesworth et al.
5,736,396	04/1998	Bruder et al.
5,811,094	09/1998	Caplan et al
5,827,740	10/1998	Pittenger
5,837,539	11/1998	Caplan et al.
5,855,619	01/1999	Caplan et al.
5,908,782	06/1999	Marshak et al.
5,908,784	06/1999	Johnstone et al.
5,942,225	08/1999	Bruder et al.
5,965,436	10/1999	Thiede et al.
6,010,696	01/2000	Caplan et al.
6,022,540	02/2000	Bruder et al.
6,030,836	02/2000	Thiede et al.
6,087,113	07/2000	Caplan et al.
6,149,906	11/2000	Mosca
6,174,333	01/2001	Kadiyala et al.
6,225,119	05/2001	Qasba et al.
6,239,157	05/2001	Mbalaviele
6,255,112	07/2001	Thiede et al.

6,261,549	07/2001	Fernandez et al.
6,281,012	08/2001	McIntosh et al.
6,322,784	11/2001	Pittenger et al.
6,328,960	12/2001	McIntosh et al.
6,342,370	01/2002	Connolly et al.
6,355,239	03/2002	Bruder et al.
6,358,702	03/2002	Connolly
6,368,636	04/2002	McIntosh et al.
6,379,953	04/2002	Bruder et al.
6,387,369	05/2002	Pittenger et al.
6,387,367	05/2002	Davis-Sproul et al.
6,482,231	11/2002	Abatangelo et al.
6,541,024	04/2003	Kadiyala et al.
6,685,936	02/2004	McIntosh et al.

Abkowitz JL et al.; "Multilineage, non-species specific hematopoietic growth factor(s) elaborated by a feline fibroblast cell line: enhancement by virus infection;" J Cell Physiol. 1986 Apr;127(1):189-96. Abstract.

Agbulut O. et al.; "Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy;" Cardiovasc Res. 2003 May 1;58(2):451-9. Abstract.

Angelopoulou M. et al.; "Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice;" Exp Hematol. 2003 May;31(5):413-20. Abstract.

Anker PS et al.; "Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice;" Exp Hematol. 2003 Oct;31(10):881-9. Abstract.

Ballas CB et al; "Adult bone marrow stem cells for cell and gene therapies: implications for greater use;" J Cell Biochem Suppl. 2002;38:20-8. Abstract.

Barry FP; "Biology and clinical applications of mesenchymal stem cells;" Birth Defects Res Part C Embryo Today. 2003 Aug;69(3):250-6. Abstract.

Bensidhoum M. et al.; "Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the nod/scid mouse. Their role in supporting human CD34 cell engraftment;" Blood. 2004 Jan 8 [Epub ahead of print]. Abstract

Bonnet D.; "Biology of human bone marrow stem cells;" Clin Exp Med. 2003 Nov;3(3):140-9. Abstract.

Bron D et al.; [Hematopoietic stem cells: source, indications and perspectives] [Article in French]; Bull Mem Acad R Med Belg. 2002;157(1-2):135-45; discussion 145-6. Abstract.

Bueren JA et al.; "Genetic modification of hematopoietic stem cells: recent advances in the gene therapy of inherited diseases;" Arch Med Res. 2003 Nov-Dec;34(6):589-99. Abstract.

Burt RK; "Hematopoietic stem cell therapy for type 1 diabetes: induction of tolerance and

islet cell neogenesis;" Autoimmun Rev. 2002 May;1(3):133-8. Abstract.

Caplan AI et al.; "Cell-based tissue engineering therapies: the influence of whole body physiology;" Adv Drug Deliv Rev. 1998 Aug 3;33(1-2):3-14. Abstract.

Cashman JD et al.; "Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-beta. Blood. 1990 Jan 1;75(1):96-101. Abstract.

Chapel A.; "Mesenchymal stem cells home to injured tissues when coinfused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome;" J Gene Med. 2003 Dec;5(12):1028-38. Abstract.

Cheng L et al.; "Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells;" J Cell Physiol. 2000 Jul;184(1):58-69. Abstract.

Deans RJ et al.; "Mesenchymal stem cells: biology and potential clinical uses;" Exp Hematol. 2000 Aug;28(8):875-84. Abstract.

Delwiche F et al.; "Platelet-derived growth factor enhances in vitro erythropoiesis via stimulation of mesenchymal cells;" J Clin Invest. 1985 Jul;76(1):137-42. Abstract.

Devine SM et al.; "Role of mesenchymal stem cells in hematopoietic stem cell transplantation;" Curr Opin Hematol. 2000 Nov;7(6):358-63. Abstract.

Devine SM et al; "Mesenchymal stem cells: stealth and suppression;" Cancer J. 2001 Nov-Dec;7 Suppl 2:S76-82. Abstract.

Dooley DC et al.; "Basic fibroblast growth factor and epidermal growth factor downmodulate the growth of hematopoietic cells in long-term stromal cultures;" J Cell Physiol. 1995 Nov;165(2):386-97. Abstract.

Eaves CJ et al.; "Regulation of hemopoietic progenitor cell proliferation;" Behring Inst Mitt. 1988 Aug;(83):85-92. Abstract.

Fibbe WE et al; "Ex vivo expansion and engraftment potential of cord blood-derived CD34+ cells in NOD/SCID mice;" Ann N Y Acad Sci. 2001 Jun;938:9-17. Abstract.

Fibbe WE; "Mesenchymal stem cells and hematopoietic stem cell transplantation;" Ann N Y Acad Sci. 2003 May;996:235-44. Abstract.

Forbes SJ et al.; "Adult stem cell plasticity: new pathways of tissue regeneration become visible.;" Clin Sci (Lond) 2002 Oct;103(4):355-69. Abstract.

Forbes SJ et al.; "Hepatic and renal differentiation from blood-borne stem cells;" Gene Ther 2002 May;9(10):625-30. Abstract.

Friedenstein; Exp. Hematol. 4:267-74, 1976.

Heike T et al.; "Stem cell plasticity in the hematopoietic system;" Int J Hematol. 2004 Jan;79(1):7-14. Abstract.

Hirschi KK et al; "Hematopoietic, vascular and càrdiac fates of bone marrow-derived stem cells;" Gene Ther. 2002 May;9(10):648-52. Abstract.

Horwitz EM.; "Bone marrow transplantation: it's not just about blood anymore!;" Pediatr Transplant. 2003;7 Suppl 3:56-8. Abstract.

Horwitz EM; Stem cell plasticity: the growing potential of cellular therapy. Arch Med Res. 2003 Nov-Dec;34(6):600-6. Abstract.

Hughes S.; "Cardiac stem cells;" J Pathol. 2002 Jul;197(4):468-78. Abstract.

Imai E et al.; "Can bone marrow differentiate into renal cells?;" Pediatr Nephrol 2002 Oct;17(10):790-4. Abstract.

Imasawa T et al.; "The potential of bone marrow-derived cells to differentiate to glomerular

mesangial cells;" J Am Soc Nephrol. 2001 Jul;12(7):1401-9. Abstract.

Ito T et al.; "Application of bone marrow-derived stem cells in experimental nephrology;" Exp Nephrol. 2001;9(6):444-50. Abstract.

Justesen J et al.; [Mesenchymal stem cells. Potential use in cell and gene therapy of bone loss

caused by aging and osteoporosis] [Article in Danish]; Ugeskr Laeger. 2001 Oct 1;163(40):5491-5. Abstract.

Kadereit S et al.; "Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer;" Stem Cells. 2002;20(6):573-82. Abstract.

Kato Y. et al.; "Recipient non-hematopoietic bone marrow cells in the intestinal graft after fetal small intestinal transplantation.;" Pediatr Surg Int. 2004 Jan;20(1):1-4. Epub 2004 Feb 01. Abstract.

Kim, J.H. et al.; Co-transplantation of ex-vivo culture-expanded human mesenchymal stem cells and allogeneic hematopoietic stem cell transplantation-report of 12 cases; Blood; December 2002, vol. 100 No. 11; meeting abstract 4234.

Koc ON et al.; "Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy;" J Clin Oncol. 2000 Jan;18(2):307-16. Abstract.

Krause DS.; "Plasticity of marrow-derived stem cells;" Gene Ther 2002 Jun;9(11):754-8. Abstract.

Kucia M. et al.; "Tissue-specific muscle, neural and liver stem/progenitor cells reside in the

bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral

blood during stress and tissue injury.;" Blood Cells Mol Dis. 2004 Jan-Feb;32(1):52-7. Abstract.

Le Blanc K.; [Mesenchymal stem cells. Basic science and future clinical use] [Article in Swedish]; Lakartidningen. 2002 Mar 21;99(12):1318-21, 1324. Abstract.

Lee K et al.; "Human mesenchymal stem cells maintain transgene expression during expansion and Differentiation;" Mol Ther. 2001 Jun; 3(6):857-66. Abstract.

Mackenzie TC et al.; "Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep;" Blood Cells Mol Dis. 2001 May-Jun;27(3):601-4. Abstract.

Majumdar MK et al.; "Characterization and functionality of cell surface molecules on human

mesenchymal stem cells;" J Biomed Sci. 2003 Mar-Apr;10(2):228-41. Abstract.

Maitra B et al.; "Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation"; Bone Marrow Transplant. 2004 Mar;33(6):597-604. Abstract.

Mbalaviele G et al.; "Human mesenchymal stem cells promote human osteoclast differentiation from CD34+bone marrow hematopoietic progenitors;" Endocrinology. 1999 Aug;140(8):3736-43. Abstract.

Noort WA et al; "Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived;" CD34(+) cells in NOD/SCID mice;" Exp Hematol. 2002 Aug;30(8):870-8. Abstract.

Orlic D; "Adult bone marrow stem cells regenerate myocardium in ischemic heart disease;" Ann N Y Acad Sci. 2003 May;996:152-7. Abstract.

Poulsom R.; "Does bone marrow contain renal precursor cells?;" Nephron Exp Nephrol 2003;93(2):e53. Abstract.

Ratajczak MZ; "Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells 'hide out' in the bone marrow;" Leukemia. 2004 Jan;18(1):29-40. Abstract.

Ringe J et al.; "Stem cells for regenerative medicine: advances in the engineering of tissues and organs;" Naturwissenschaften. 2002 Aug;89(8):338-51. Epub 2002 Jul 23. Abstract.

Tocci A. et al.; "Mesenchymal stem cell: use and perspectives;" Hematol J. 2003;4(2):92-6. Abstract.

Tuan RS et al.; "Adult mesenchymal stem cells and cell-based tissue engineering;" Arthritis Res Ther. 2003;5(1):32-45. Epub 2002 Dec 11. Abstract.

Van Damme A et al; "Bone marrow stromal cells as targets for gene therapy:" Curr Gene Ther. 2002 May;2(2):195-209. Abstract.

Yokoo T et al.; "Stem cell gene therapy for chronic renal failure;" Curr Gene Ther. 2003 Oct;3(5):387-94. Abstract.

Zhu GR et al.; [Human bone marrow mesenchymal stem cells express multiple hematopoietic growth factors] [Article in Chinese]; Zhou XY, Lu H, Zhou JW, Li AP, Xu W, Li JY, Wang CY. Abstract.

Shi C et al.; [Prospects of Research on Bone Marrow Mesenchymal Stem Cells] [Article in Chinese]; Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2000 Mar;8(1):61-65. Abstract.

Chen JL et al.; [Mesenchymal stem cells suppress allogeneic T cell responses by secretion of

TGF-beta1] [Article in Chinese]; Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002 Aug;10(4):285-8.

International Search Report dated December 12, 2004 from International Application No. PCT/US04/09922.

Applicant is enclosing Form PTO-1449 (five sheets), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). As each of the listed references is in English, no further commentary is believed to be necessary, 37 C.F.R §1.98(a)(3). Applicant respectfully requests the Examiner's consideration of the above references and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

Applicant has calculated no fee to be due in connection with the filing of this Statement. However, the Director is authorized to charge any fee deficiency associated with the filing of this Statement to a deposit account, as authorized in the Transmittal accompanying this Statement.

Respectfully submitted,

June 21, 2006

Date

Heidi A. Dare (Reg. No. 50,775)

\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
FORM PTO-1449	SERIAL NO.	CASE NO.
	10/551,317	10402-26
LIST OF PATENTS AND POSICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE	September 29, 2005	To Be Assigned
STATEMENT		
(use several sheets if necessary)	APPLICANT: Christof Westenfe	lder

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER Number-Kind Code (if known)	DATE	NAME	CLASS/ SUBCLASS	FILING
	A1	5,197,985	03/1993	Caplan et al.		
	A2	5,226,914	07/1996	Caplan et al.		
	A3	5,486,359	01/1996	Caplan et al.		
	A4	5,591,625	01/1997	Gerson et al.		
	A5	5,643,736	07/1997	Bruder et al.		
**************************************	A6	5,733,542	03/1998	Haynesworth et al.		
	A7	5,736,396	04/1998	Bruder et al.		
	A8	5,811,094	09/1998	Caplan et al		
	A9	5,827,740	10/1998	Pittenger		
	A10	5,837,539	11/1998	Caplan et al.		
	A11	5,855,619	01/1999	Caplan et al.		
	A12	5,876,708 A	03/1999	Sachs		
, ,	A13	5,908,782	06/1999	Marshak et al.		
	A14	5,908,784	06/1999	Johnstone et al.		
	A15	5,942,225	08/1999	Bruder et al.		
	A16	5,965,436	10/1999	Thiede et al.		
	A17	6,010,696	01/2000	Caplan et al.		
•	A18	6,022,540	02/2000	Bruder et al.		
<del></del>	A19	6,030,836	02/2000	Thiede et al.		
	A20	6,087,113	07/2000	Caplan et al.		
	A21	6,149,906	11/2000	Mosca		
	A22	6,174,333	01/2001	Kadiyala et al.		
	A23	6,225,119	05/2001	Qasba et al.		
	A24	6,239,157	05/2001	Mbalaviele		
	A25	6,255,112	07/2001	Thiede et al.		
	A26	6,261,549	07/2001	Fernandez et al.		
	A27	6,281,012	08/2001	McIntosh et al.		
	A28	6,322,784	11/2001	Pittenger et al.		
	A29	6,328,960	12/2001	McIntosh et al.		
40	A30	6,342,370	01/2002	Connolly et al.		
	A31	6,355,239	03/2002	Bruder et al.		
	A32	6,358,702	03/2002	Connolly		
	A33	6,368,636	04/2002	McIntosh et al.		
	A34	6,379,953	04/2002	Bruder et al.		
-	A35	6,387,369	05/2002	Pittenger et al.		
	A36	6,387,367	05/2002	Davis-Sproul et al.		
**************************************	A37	6,482,231	11/2002	Abatangelo et al.		
	A38	6,541,024	04/2003	Kadiyala et al.		
	A39	6,685,936	02/2004	McIntosh et al.		

EXAMINER DATE CONSIDERED

Page 2 of 5

FORM PTO-1449	SERIAL NO.	CASE NO.
	10/551,317	10402-26
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE	September 29, 2005	To Be Assigned
STATEMENT		
(use several sheets if necessary)	APPLICANT: Christof Westenfe	lder

## **REFERENCE DESIGNATION**

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER Number-Kind Code (if known)	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A40					

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER Number-Kind Code (if known)	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
<u> </u>					

EXAMINER INITIAL	. ,	OTHER ART – NON PATENT LITERATURE DOCUMENTS clude name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, posium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.
	A41	Abkowitz JL et al.; "Multilineage, non-species specific hematopoietic growth factor(s) elaborated by a feline fibroblast cell line: enhancement by virus infection;" J Cell Physiol. 1986 Apr;127(1):189-96. Abstract.
	A42	Agbulut O. et al.; "Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy;" Cardiovasc Res. 2003 May 1;58(2):451-9. Abstract.
<u>.</u>	A43	Angelopoulou M. et al.; "Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice;" Exp Hematol. 2003 May;31(5):413-20. Abstract.
	A44	Anker PS et al.; "Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice;" Exp Hematol. 2003 Oct;31(10):881-9. Abstract.
	A45	Ballas CB et al; "Adult bone marrow stem cells for cell and gene therapies: implications for greater use;" J Cell Biochem Suppl. 2002;38:20-8. Abstract.
	A46	Barry FP; "Biology and clinical applications of mesenchymal stem cells;" Birth Defects Res Part C Embryo Today. 2003 Aug;69(3):250-6. Abstract.
	A47	Bensidhoum M. et al.; "Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the nod/scid mouse. Their role in supporting human CD34 cell engraftment;" Blood. 2004 Jan 8 [Epub ahead of print]. Abstract
	A48	Bonnet D.; "Biology of human bone marrow stem cells;" Clin Exp Med. 2003 Nov;3(3):140-9. Abstract.
	A49	Bron D et al.; [Hematopoietic stem cells: source, indications and perspectives] [Article in French]; Bull Mem Acad R Med Belg. 2002;157(1-2):135-45; discussion 145-6. Abstract.
	A50	Bueren JA et al.; "Genetic modification of hematopoietic stem cells: recent advances in the gene therapy of inherited diseases;" Arch Med Res. 2003 Nov-Dec;34(6):589-99. Abstract

	gene therapy of inherited	diseases;" Arch Med Res.	2003 Nov-Dec;34(6):589-99.	Abstract
EXAMINER		DATE CONSIDERED		

Page 3 of 5

		i age o oi o
FORM PTO-1449	SERIAL NO.	CASE NO.
	10/551,317	10402-26
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE	September 29, 2005	To Be Assigned
STATEMENT		
(use several sheets if necessary)	APPLICANT: Christof Westenfe	lder

EXAMINER		OTHER ART - NON PATENT LITERATURE DOCUMENTS
INITIAL	(In	clude name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, posium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.
	A51	Burt RK; "Hematopoietic stem cell therapy for type 1 diabetes: induction of tolerance and
	A 50	islet cell neogenesis;" Autoimmun Rev. 2002 May;1(3):133-8. Abstract.
	A52	Caplan AI et al.; "Cell-based tissue engineering therapies: the influence of whole body physiology;" Adv Drug Deliv Rev. 1998 Aug 3;33(1-2):3-14. Abstract.
	A53	Cashman JD et al.; "Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-beta. Blood. 1990 Jan 1;75(1):96-101. Abstract.
- <del> </del>	A54	Chapel A.; "Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome;" J Gene Med. 2003 Dec;5(12):1028-38. Abstract.
	A55	Cheng L et al.; "Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells;" J Cell Physiol. 2000 Jul;184(1):58-69. Abstract.
	A56	Deans RJ et al.; "Mesenchymal stem cells: biology and potential clinical uses;" Exp Hematol. 2000 Aug;28(8):875-84. Abstract.
·	A57	Delwiche F et al.; "Platelet-derived growth factor enhances in vitro erythropoiesis via stimulation of mesenchymal cells;" J Clin Invest. 1985 Jul;76(1):137-42. Abstract.
	A58	Devine SM et al.; "Role of mesenchymal stem cells in hematopoietic stem cell transplantation;" Curr Opin Hematol. 2000 Nov;7(6):358-63. Abstract.
	A59	Devine SM et al; "Mesenchymal stem cells: stealth and suppression;" Cancer J. 2001 Nov-Dec;7 Suppl 2:S76-82. Abstract.
	A60	Dooley DC et al.; "Basic fibroblast growth factor and epidermal growth factor downmodulate the growth of hematopoietic cells in long-term stromal cultures;" J Cell Physiol. 1995 Nov;165(2):386-97. Abstract.
	A61	Eaves CJ et al.; "Regulation of hemopoietic progenitor cell proliferation;" Behring Inst Mitt. 1988 Aug;(83):85-92. Abstract.
	A62	Fibbe WE et al; "Ex vivo expansion and engraftment potential of cord blood-derived CD34+ cells in NOD/SCID mice;" Ann N Y Acad Sci. 2001 Jun;938:9-17. Abstract.
	A63	Fibbe WE; "Mesenchymal stem cells and hematopoietic stem cell transplantation;" Ann N Y Acad Sci. 2003 May;996:235-44. Abstract.
	A64	Forbes SJ et al.; "Adult stem cell plasticity: new pathways of tissue regeneration become visible.;" Clin Sci (Lond) 2002 Oct;103(4):355-69. Abstract.
	A65	Forbes SJ et al.; "Hepatic and renal differentiation from blood-borne stem cells;" Gene Ther 2002 May;9(10):625-30. Abstract.
	A66	Friedenstein; Exp. Hematol. 4:267-74, 1976.
	A67	Heike T et al.; "Stem cell plasticity in the hematopoietic system;" Int J Hematol. 2004 Jan;79(1):7-14. Abstract.
	A68	Hirschi KK et al; "Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells;" Gene Ther. 2002 May;9(10):648-52. Abstract.

-VARAINED	DATE CONCIDEDED	
EXAMINER	DATE CONSIDERED	

Page 4 of 5

•		1 age 4 01 J
FORM PTO-1449	SERIAL NO.	CASE NO.
	10/551,317	10402-26
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE	September 29, 2005	To Be Assigned
STATEMENT		
(use several sheets if necessary)	APPLICANT: Christof Westenfe	lder

EXAMINER	/In	OTHER ART – NON PATENT LITERATURE DOCUMENTS clude name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial,
INITIAL	sym	posium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.
	A69	Horwitz EM.; "Bone marrow transplantation: it's not just about blood anymore!;" Pediatr
		Transplant. 2003;7 Suppl 3:56-8. Abstract.
	A70	Horwitz EM; Stem cell plasticity: the growing potential of cellular therapy. Arch Med Res.
<del>, , , , , , , , , , , , , , , , , , , </del>		2003 Nov-Dec;34(6):600-6. Abstract.
	A71	Hughes S.; "Cardiac stem cells;" J Pathol. 2002 Jul;197(4):468-78. Abstract.
	A72	Imai E et al.; "Can bone marrow differentiate into renal cells?;" Pediatr Nephrol 2002 Oct;17(10):790-4. Abstract.
	A73	Imasawa T et al.; "The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells;" J Am Soc Nephrol. 2001 Jul;12(7):1401-9. Abstract.
	A74	Ito T et al.; "Application of bone marrow-derived stem cells in experimental nephrology;" Exp Nephrol. 2001;9(6):444-50. Abstract.
1 - I	A75	Justesen J et al.; [Mesenchymal stem cells. Potential use in cell and gene therapy of bone loss
		caused by aging and osteoporosis] [Article in Danish]; Ugeskr Laeger. 2001 Oct 1;163(40):5491-5. Abstract.
	A76	Kadereit S et al.; "Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer;" Stem Cells. 2002;20(6):573-82. Abstract.
	A77	Kato Y. et al.; "Recipient non-hematopoietic bone marrow cells in the intestinal graft after fetal small intestinal transplantation.;" Pediatr Surg Int. 2004 Jan;20(1):1-4. Epub 2004 Feb 01. Abstract.
	A78	Kim, J.H. et al.; Co-transplantation of ex-vivo culture-expanded human mesenchymal stem cells and allogeneic hematopoietic stem cell transplantation-report of 12 cases; Blood; December 2002, vol. 100 No. 11; meeting abstract 4234.
	A79	Koc ON et al.; "Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy;" J Clin Oncol. 2000 Jan; 18(2):307-16. Abstract.
	A80	Krause DS.; "Plasticity of marrow-derived stem cells;" Gene Ther 2002 Jun;9(11):754-8.  Abstract.
	A81	Kucia M. et al.; "Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury.;" Blood Cells Mol Dis. 2004 Jan-Feb;32(1):52-7. Abstract.
	A82	Le Blanc K.; [Mesenchymal stem cells. Basic science and future clinical use] [Article in Swedish]; Lakartidningen. 2002 Mar 21;99(12):1318-21, 1324. Abstract.
	A83	Lee K et al.; "Human mesenchymal stem cells maintain transgene expression during expansion and Differentiation;" Mol Ther. 2001 Jun; 3(6):857-66. Abstract.
	A84	Mackenzie TC et al.; "Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep;" Blood Cells Mol Dis. 2001 May-Jun;27(3):601-4. Abstract.

EXAMINER	DATE CONSIDERED	

Page 5 of 5

		i ago o oi o
FORM PTO-1449	SERIAL NO.	CASE NO.
	10/551,317	10402-26
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE	September 29, 2005	To Be Assigned
STATEMENT		
(use several sheets if necessary)	APPLICANT: Christof Westenfe	der

EXAMINER INITIAL	(Inc	OTHER ART – NON PATENT LITERATURE DOCUMENTS lude name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, osium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.
	A85	Majumdar MK et al.; "Characterization and functionality of cell surface molecules on human mesenchymal stem cells;" J Biomed Sci. 2003 Mar-Apr;10(2):228-41. Abstract.
	A86	Maitra B et al.; "Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation"; Bone Marrow Transplant. 2004 Mar;33(6):597-604. Abstract.
	A87	Mbalaviele G et al.; "Human mesenchymal stem cells promote human osteoclast differentiation from CD34+bone marrow hematopoietic progenitors;" Endocrinology. 1999 Aug;140(8):3736-43. Abstract.
	A88	Noort WA et al; "Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived;" CD34(+) cells in NOD/SCID mice;" Exp Hematol. 2002 Aug;30(8):870-8. Abstract.
	A89	Orlic D; "Adult bone marrow stem cells regenerate myocardium in ischemic heart disease;" Ann N Y Acad Sci. 2003 May;996:152-7. Abstract.
	A90	Poulsom R.; "Does bone marrow contain renal precursor cells?;" Nephron Exp Nephrol 2003;93(2):e53. Abstract.
	A91	Ratajczak MZ; "Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells 'hide out' in the bone marrow;" Leukemia. 2004 Jan;18(1):29-40. Abstract.
	A92	Ringe J et al.; "Stem cells for regenerative medicine: advances in the engineering of tissues and organs;" Naturwissenschaften. 2002 Aug;89(8):338-51. Epub 2002 Jul 23. Abstract.
	A93	Tocci A. et al.; "Mesenchymal stem cell: use and perspectives;" Hematol J. 2003;4(2):92-6.  Abstract.
	A94	Tuan RS et al.; "Adult mesenchymal stem cells and cell-based tissue engineering;" Arthritis Res Ther. 2003;5(1):32-45. Epub 2002 Dec 11. Abstract.
	A95	Van Damme A et al; "Bone marrow stromal cells as targets for gene therapy:" Curr Gene Ther. 2002 May;2(2):195-209. Abstract.
	A96	Yokoo T et al.; "Stem cell gene therapy for chronic renal failure;" Curr Gene Ther. 2003 Oct;3(5):387-94. Abstract.
	A97	Zhu GR et al.; [Human bone marrow mesenchymal stem cells express multiple hematopoietic growth factors] [Article in Chinese]; Zhou XY, Lu H, Zhou JW, Li AP, Xu W, Li JY, Wang CY. Abstract.
**	A98	Shi C et al.; [Prospects of Research on Bone Marrow Mesenchymal Stem Cells] [Article in Chinese]; Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2000 Mar;8(1):61-65. Abstract.
	A99	Chen JL et al.; [Mesenchymal stem cells suppress allogeneic T cell responses by secretion of TGF-beta1] [Article in Chinese]; Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002 Aug;10(4):285-8.
	A100	International Search Report dated December 12, 2004 from International Application No. PCT/US04/09922.

EXAMINER	DATE CONSIDERED